Life Tech Hearts Synth Bio, Shows Venter Some Love

Jun 03, 2010

Over at Forbes' The Science Business blog, Matthew Herper reports on Life Technologies' $100 million investment in synthetic biology — including its recent acquisition of a majority stake in Geneart, and an equity investment

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Not Going With Verily

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

From Bread Bakery to Lab Space

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

Decline in Antibodies

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

PNAS Papers on Diabetic Kidney Disease, Spontaneous Diploid Yeast Mutations, More

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.

Menu